The Myeloid Panel enables concurrent analysis of both DNA and RNA from blood and bone marrow samples in a single assay to study biomarkers associated with hematologic malignancies. The panel covers relevant targets for these major myeloid disorders: acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML). Key features include:
The Myeloid Panel is part of an integrated workflow that includes AmpliSeq for Illumina polymerase chain reaction (PCR)-based library preparation, Illumina sequencing by synthesis (SBS), NGS technology, and automated analysis.
The ready-to-use panel saves you the time and effort of identifying targets, designing primers, and optimizing panels.
| Instrument | Recommended Number of Samples | Read Length |
|---|---|---|
| MiniSeq System | Samples per run (mid output): 4 DNA, 32 RNA, 3 combined samples (based on >95% at 500x minimum coverage) Samples per run (high output): 12 DNA, 96 RNA, 11 combined samples (based on >95% at 500x minimum coverage) |
2 x 151 bp 2 x 151 bp |
| MiSeq System | Samples per run with v2 reagents: 7 DNA, 60 RNA, 6 combined samples Samples per run with v3 reagents: 12 DNA, 96 RNA, 11 combined samples |
2 x 151 bp 2 x 151 bp |
| AmpliSeq for Illumina Myeloid Panel | AmpliSeq for Illumina Cancer Hotspot Panel v2 | TruSight Myeloid Sequencing Panel | |
|---|---|---|---|
| Assay Time | 5.5 – 7.5 hours (library prep only; doesn't include library quantification, normalization, or pooling time) | 5 hours (library prep only; doesn't include library quantification, normalization, or pooling time) | 8 hours |
| Cancer Type | Hematologic | Pan-Cancer, Solid Tumor | Hematologic |
| Content Specifications | Targets biomarkers across 69 genes (40 key DNA target genes, 29 RNA fusion driver genes, and 5 gene expression levels) | Hotspot regions of 50 genes with known associations to cancer | Targets 54 genes associated with myeloid malignancies. Probes amplify 568 amplicons from tumor suppressor genes and mutational hotspots. |
| Description | Targeted panel to study 40 DNA genes, 29 RNA fusion driver genes, and 5 gene expression levels associated with myeloid cancers. | Somatic analysis research into hotspot regions of 50 cancer-related genes. | For somatic mutation detection studies in myeloid malignancies. |
| Hands-On Time | < 1.5 hours | < 1.5 hours | 3 hours |
| Input Quantity | 20 ng high-quality DNA; 10 ng high-quality RNA (10 ng recommended per pool) |
1–100 ng (10 ng recommended per pool) | 50 ng |
| Method | Amplicon Sequencing, Targeted DNA Sequencing, Targeted RNA Sequencing | Amplicon Sequencing, Targeted DNA Sequencing | Amplicon Sequencing, Targeted DNA Sequencing |
| Multiplexing | Up to 96-plex | 96 dual index combinations | Up to 96-plex |
| Nucleic Acid Type | RNA, DNA | DNA | DNA |
| Specialized Sample Types | Blood, Bone Marrow, Not FFPE-Compatible | FFPE Tissue | Not FFPE-Compatible |
| Species Category | Human | Human | Human |
Automated Solutions for AmpliSeq for Illumina Sequencing Panels
Application Note | HTML
AmpliSeq for Illumina Myeloid Panel Data Sheet
Data Sheet | HTML
Illumina Adapter Sequences Documentation
AmpliSeq for Illumina Myeloid Panel Documentation
AmpliSeq for Illumina Myeloid Panel Reference Guide Documentation
AmpliSeq for Illumina Myeloid Panel Consumables & Equipment Documentation
AmpliSeq for Illumina Myeloid Panel Checklist Documentation
Index Adapters Pooling Guide Documentation
Custom Protocol Selector
Generates customized, end-to-end instructions
Targeted DNA and RNA research panel investigating variants across 161 genes associated with a range of cancer types.
Targeted research panel investigating hotspot regions of 50 genes with known associations to cancer.
Targeted DNA and RNA research panel investigating 52 genes with known relevance to solid tumors.
Targeted panel that measures expression levels of >20,000 human RefSeq genes.
Targeted research panel investigating somatic and germline variants in BRCA1 and BRCA2.
These sequencing reagent kits offer increased stability and robustness over the v2 kit version.
